Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine as Adjuvant Chemotherapy in Nasopharyngeal Carcinoma
NCT02958111Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2017
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02958111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958111.